Since CYP3A5 is the major extrahepatic CYP3A isoform expressed in prostate and regulates AR activation, the presence of these SNPs in CYP3A5 may alter prostate cancer occurrence growth and treatment resistance in a race-dependent manner. This evidence concerns the gene CYP3A5 and prostate cancer.